301 related articles for article (PubMed ID: 22666441)
21. Intracellular accumulation and reduced sarcolemmal expression of dysferlin in limb--girdle muscular dystrophies.
Piccolo F; Moore SA; Ford GC; Campbell KP
Ann Neurol; 2000 Dec; 48(6):902-12. PubMed ID: 11117547
[TBL] [Abstract][Full Text] [Related]
22. Secreted acid sphingomyelinase as a potential gene therapy for limb girdle muscular dystrophy 2B.
Bittel DC; Sreetama SC; Chandra G; Ziegler R; Nagaraju K; Van der Meulen JH; Jaiswal JK
J Clin Invest; 2022 Jan; 132(1):. PubMed ID: 34981776
[TBL] [Abstract][Full Text] [Related]
23. Proteasomal inhibition restores biological function of mis-sense mutated dysferlin in patient-derived muscle cells.
Azakir BA; Di Fulvio S; Kinter J; Sinnreich M
J Biol Chem; 2012 Mar; 287(13):10344-10354. PubMed ID: 22318734
[TBL] [Abstract][Full Text] [Related]
24. Recessive mutations in the putative calcium-activated chloride channel Anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular dystrophies.
Bolduc V; Marlow G; Boycott KM; Saleki K; Inoue H; Kroon J; Itakura M; Robitaille Y; Parent L; Baas F; Mizuta K; Kamata N; Richard I; Linssen WH; Mahjneh I; de Visser M; Bashir R; Brais B
Am J Hum Genet; 2010 Feb; 86(2):213-21. PubMed ID: 20096397
[TBL] [Abstract][Full Text] [Related]
25. Myofibers deficient in connexins 43 and 45 expression protect mice from skeletal muscle and systemic dysfunction promoted by a dysferlin mutation.
Fernández G; Arias-Bravo G; Bevilacqua JA; Castillo-Ruiz M; Caviedes P; Sáez JC; Cea LA
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165800. PubMed ID: 32305450
[TBL] [Abstract][Full Text] [Related]
26. Phenotypic study in 40 patients with dysferlin gene mutations: high frequency of atypical phenotypes.
Nguyen K; Bassez G; Krahn M; Bernard R; Laforêt P; Labelle V; Urtizberea JA; Figarella-Branger D; Romero N; Attarian S; Leturcq F; Pouget J; Lévy N; Eymard B
Arch Neurol; 2007 Aug; 64(8):1176-82. PubMed ID: 17698709
[TBL] [Abstract][Full Text] [Related]
27. Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B.
Nagaraju K; Rawat R; Veszelovszky E; Thapliyal R; Kesari A; Sparks S; Raben N; Plotz P; Hoffman EP
Am J Pathol; 2008 Mar; 172(3):774-85. PubMed ID: 18276788
[TBL] [Abstract][Full Text] [Related]
28. Dysferlinopathies: Clinical and genetic variability.
Ivanova A; Smirnikhina S; Lavrov A
Clin Genet; 2022 Dec; 102(6):465-473. PubMed ID: 36029111
[TBL] [Abstract][Full Text] [Related]
29. Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer.
Grose WE; Clark KR; Griffin D; Malik V; Shontz KM; Montgomery CL; Lewis S; Brown RH; Janssen PM; Mendell JR; Rodino-Klapac LR
PLoS One; 2012; 7(6):e39233. PubMed ID: 22720081
[TBL] [Abstract][Full Text] [Related]
30. Dysferlinopathy: a clinical and histopathological study of 28 patients from India.
Nalini A; Gayathri N
Neurol India; 2008; 56(3):379-85; discussion 386-7. PubMed ID: 18974568
[TBL] [Abstract][Full Text] [Related]
31. Dysferlin deficiency and the development of cardiomyopathy in a mouse model of limb-girdle muscular dystrophy 2B.
Chase TH; Cox GA; Burzenski L; Foreman O; Shultz LD
Am J Pathol; 2009 Dec; 175(6):2299-308. PubMed ID: 19875504
[TBL] [Abstract][Full Text] [Related]
32. Late onset in dysferlinopathy widens the clinical spectrum.
Klinge L; Dean AF; Kress W; Dixon P; Charlton R; Müller JS; Anderson LV; Straub V; Barresi R; Lochmüller H; Bushby K
Neuromuscul Disord; 2008 Apr; 18(4):288-90. PubMed ID: 18396043
[TBL] [Abstract][Full Text] [Related]
33. Genetic manipulation of dysferlin expression in skeletal muscle: novel insights into muscular dystrophy.
Millay DP; Maillet M; Roche JA; Sargent MA; McNally EM; Bloch RJ; Molkentin JD
Am J Pathol; 2009 Nov; 175(5):1817-23. PubMed ID: 19834057
[TBL] [Abstract][Full Text] [Related]
34. AMPK Complex Activation Promotes Sarcolemmal Repair in Dysferlinopathy.
Ono H; Suzuki N; Kanno SI; Kawahara G; Izumi R; Takahashi T; Kitajima Y; Osana S; Nakamura N; Akiyama T; Ikeda K; Shijo T; Mitsuzawa S; Nagatomi R; Araki N; Yasui A; Warita H; Hayashi YK; Miyake K; Aoki M
Mol Ther; 2020 Apr; 28(4):1133-1153. PubMed ID: 32087766
[TBL] [Abstract][Full Text] [Related]
35. Structure-Based Designed Nano-Dysferlin Significantly Improves Dysferlinopathy in BLA/J Mice.
Llanga T; Nagy N; Conatser L; Dial C; Sutton RB; Hirsch ML
Mol Ther; 2017 Sep; 25(9):2150-2162. PubMed ID: 28629822
[TBL] [Abstract][Full Text] [Related]
36. Minimal expression of dysferlin prevents development of dysferlinopathy in dysferlin exon 40a knockout mice.
Yasa J; Reed CE; Bournazos AM; Evesson FJ; Pang I; Graham ME; Wark JR; Nijagal B; Kwan KH; Kwiatkowski T; Jung R; Weisleder N; Cooper ST; Lemckert FA
Acta Neuropathol Commun; 2023 Jan; 11(1):15. PubMed ID: 36653852
[TBL] [Abstract][Full Text] [Related]
37. GREG cells, a dysferlin-deficient myogenic mouse cell line.
Humphrey GW; Mekhedov E; Blank PS; de Morree A; Pekkurnaz G; Nagaraju K; Zimmerberg J
Exp Cell Res; 2012 Jan; 318(2):127-35. PubMed ID: 22020321
[TBL] [Abstract][Full Text] [Related]
38. Patients with a non-dysferlin Miyoshi myopathy have a novel membrane repair defect.
Jaiswal JK; Marlow G; Summerill G; Mahjneh I; Mueller S; Hill M; Miyake K; Haase H; Anderson LV; Richard I; Kiuru-Enari S; McNeil PL; Simon SM; Bashir R
Traffic; 2007 Jan; 8(1):77-88. PubMed ID: 17132147
[TBL] [Abstract][Full Text] [Related]
39. The absence of dysferlin induces the expression of functional connexin-based hemichannels in human myotubes.
Cea LA; Bevilacqua JA; Arriagada C; Cárdenas AM; Bigot A; Mouly V; Sáez JC; Caviedes P
BMC Cell Biol; 2016 May; 17 Suppl 1(Suppl 1):15. PubMed ID: 27229680
[TBL] [Abstract][Full Text] [Related]
40. Loss of dysferlin or myoferlin results in differential defects in excitation-contraction coupling in mouse skeletal muscle.
Barefield DY; Sell JJ; Tahtah I; Kearns SD; McNally EM; Demonbreun AR
Sci Rep; 2021 Aug; 11(1):15865. PubMed ID: 34354129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
